ArticleBiological psychiatry2018
Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [
Article in Biological psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Dopamine in major depressive disorder: A systematic review and meta-analysis of in vivo imaging studies.Journal of psychopharmacology (Oxford, England) · 2023Pooled it
- Novel multi-modal methodology to investigate placebo response in major depressive disorder.Journal of affective disorders · 2025Trial
- Angiotensin blockade enhances motivational reward learning via enhancing striatal prediction error signaling and frontostriatal communication.Molecular psychiatry · 2023Trial
- Multilevel growth curve analyses of behavioral activation for anhedonia (BATA) and mindfulness-based cognitive therapy effects on anhedonia and resting-state functional connectivity: Interim results of a randomized trialJournal of affective disorders · 2021Trial
- Trajectories of late-life depression: insights from molecular imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Neurobiological mechanisms and brain network dysfunction in major depressive disorder: an integrative review.Frontiers in integrative neuroscience · 2026Review
- Striatal dopamine in anhedonia: A simultaneous [Psychiatry research. Neuroimaging · 2023Article
- What Can Reinforcement Learning Models of Dopamine and Serotonin Tell Us about the Action of Antidepressants?Computational psychiatry (Cambridge, Mass.) · 2022Review
- Influences of dopaminergic system dysfunction on late-life depression.Molecular psychiatry · 2022Review
- Differential reinforcement learning responses to positive and negative information in unmedicated individuals with depression.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2021Article
- Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?Expert opinion on pharmacotherapy · 2021Review
- Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [Molecular psychiatry · 2021Article
- Neuroendocrine Assessment of Dopaminergic Function during Antidepressant Treatment in Major Depressed Patients.Brain sciences · 2021Article
- Advances in simultaneous PET/MR for imaging neuroreceptor function.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020Review
- Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression.Brain : a journal of neurology · 2020Article
- The Mesolimbic Dopamine System in Chronic Pain and Associated Affective Comorbidities.Biological psychiatry · 2020Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundMesolimbic dopamine system dysfunction is believed to contribute to major depressive disorder (MDD), but molecular neuroimaging of striatal dopamine neurotransmission has yielded mixed results, possibly owing to limited sensitivity of antagonist radioligands used with positron emission tomography to assess dopamine release capacity. This study used an agonist radioligand with agonist challenge to assess dopamine release capacity and D
methodsTwenty-six treatment-naive adults with MDD and 26 healthy comparison participants underwent functional magnetic resonance imaging during a probabilistic reinforcement task, and positron emission tomography with the D
resultsMDD participants had trend-level greater dopamine release capacity in the ventral striatum, as measured by percent change in baseline binding potential relative to nondisplaceable compartment (ΔBP
conclusions[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.